Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures
Richard C. Becker, MD*,*,
James Scheiman, MD ,
Harold L. Dauerman, MD ,
Frederick Spencer, MD ,
Sunil Rao, MD||,
Marc Sabatine, MD¶,
David A. Johnson, MD#,
Frances Chan, MD**,
Neena S. Abraham, MD ,
Eamonn M.M. Quigley, MD in collaboration with the American College of Cardiology and the American College of Gastroenterology
* Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina
University of Michigan, Ann Arbor, Michigan
University of Vermont, Burlington, Vermont
McMaster University, Hamilton, Ontario, Canada
|| Durham VA Medical Center, Durham, North Carolina
¶ Brigham and Women's Hospital, Boston, Massachusetts
# Eastern Virginia School of Medicine, Norfolk, Virginia
** Chinese University of Hong Kong, Hong Kong, China
 Baylor College of Medicine, Houston, Texas
 National University of Ireland at Cork, Cork, Ireland

View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Risk of Clinical Events After Clopidogrel Cessation
Risk-adjusted instantaneous incidence rates of death or acute myocardial infarction over time after stopping treatment with clopidogrel among medically treated and percutaneous coronary intervention (PCI)-treated patients with acute coronary syndrome. Reprinted with permission from Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532–9.
|
|
|